Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants

NCT ID: NCT01075750

Last Updated: 2013-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study we want to show that the choice of a balanced type fluid solution for the perioperative fluid management of patients receiving cadaveric renal transplantation results in less occurrence of intra- and postoperative hyperkalemia, and thus the need for postoperative dialysis. Additionally, we aim to determine whether the use of a balanced infusion solution leads to less occurrence of metabolic acidosis and electrolyte disorders than the use of isotonic saline.

Furthermore we want to evaluate whether perioperative fluid management with balanced infusion solutions results in a higher frequency of primary graft function than with administration of isotonic saline.

We will test the hypothesis that the use of "Elomel isoton"(Fresenius Kabi Austria GmbH) a balanced infusion solution will result in less occurrence of hyperkalemia and consequent post-transplant dialysis, less occurrence of metabolic acidosis, decreased incidence of electrolyte disorders and higher incidence of primary graft function when compared to isotonic saline for perioperative fluid management in patients receiving cadaveric renal transplantation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background

Kidney transplantation is the treatment of choice for patients with end-stage-renal-disease (ESRD). Successful renal transplantation improves quality of life and reduces mortality in eligible patients when compared to hemodialysis. In 2007, 44 kidney transplantations per million residents were performed in Austria. The number of patients with a renal transplant has continuously risen in the last ten years. 398 kidney transplantations were performed in Austria in 2007, of which only 61 were of living donors. This underlines the special role of cadaveric kidney transplantation in Austria.

Several studies have demonstrated that adequate intraoperative fluid administration is associated with earlier onset of graft function and improved graft survival in renal transplant recipients. However, which kind of solution should be chosen for the perioperative fluid management of renal transplant recipients remains to be clarified. A non-governmental US survey has shown that normal saline is the most commonly used fluid for renal transplantation. The most common cited reason for the administration of normal saline was the lack of potassium in the solution. Balanced salt type fluids were used in only less than 10% of kidney transplantations.

To our knowledge only three studies compared the effects of lactated ringer's solution versus normal saline in kidney transplantation. Taken together, the application of lactated ringer's solution led to less occurrence of metabolic acidosis, electrolyte derangements and in one study, the appearance of hyperkalemia was eliminated by the use of lactated ringer's instead of normal saline. However, it was also shown that the administration of lactated ringer's during kidney transplantation led to a significant rise in lactate levels compared to those treated with normal salin. Despite the knowledge that lactated ringer's can at least potentially lead to a rise in lactate levels, no studies using acetate based balanced salt type fluids have been performed so far in cadaveric renal transplantation. We therefore propose a prospective study in which patients undergoing cadaveric kidney transplantation will be randomized to receive either a solely acetate buffered balanced salt type fluid or a normal saline for infusion therapy.

Clinical considerations

Postoperative hyperkalemia is a common problem in patients receiving cadaveric renal transplantation, especially when primary graft function does not occur. Due to the acidifying effect of isotonic saline infusion via the generation of hyperchloremic acidosis and/or dilutional acidosis, a rise in serum potassium is only boosted. However, today isotonic saline is the most commonly used infusion solution for the perioperative period in renal transplantation.

The use of a balanced infusion solution, containing a metabolizable anion, such as acetate, could result in less metabolic acidosis and therefore a decreased need for post-transplant dialysis. Moreover, since balanced infusion solutions have a by far lower chloride content than isotonic saline, the adverse effects of a rise in serum chloride on renal perfusion could be avoided. This could ultimately result in improved graft function.

Preliminary studies

O'Malley et al. compared the effects of lactated Ringer's to isotonic saline in 51 renal transplant patients. 48 patients received living donor transplantation and 3 received cadaveric renal transplantation. 26 patients received isotonic saline and 25 lactated Ringer's. 19% of patients receiving isotonic saline reached postassium concentrations \> 6mmol/L and required treatment versus 0% in the lactated Ringer's group. 31% of patients in the isotonic saline group versus 0% in the lactated Ringer's group required treatment for metabolic acidosis. No effect on primary graft function could be shown.

Hadimioglu et al. randomized patients undergoing living-related kidney transplantation to three groups receiving either isotonic saline, lactated Ringer's or Plasmalyte (a balanced infusion solution using acetate and gluconate). No effects on potassium levels could be shown in this study. Patients receiving isotonic saline showed significant decreases in pH, base excess and a significant rises in serum chloride. In the lactated Ringer's group lactate levels increased significantly. The study showed no differences in the need for postoperative dialysis.

Khajavi et al. randomized patients undergoing kidney transplantation to either normal saline or lactated Ringer's. The authors noticed a higher incidence of hyperkalemia and acidosis in the isotonic saline group while 2 patients in the lactated Ringer's group lost their kidneys due to vascular graft thrombosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperkalaemia Requiring Postoperative Dialysis Metabolic Acidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Saline

Patients receiving Normal Saline during and after the renal transplantation.

No interventions assigned to this group

Elomel Isoton

Patients receiving Elomel Isoton during and after renal transplantation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with end-stage-renal disease admitted for cadaveric renal transplantation will be included in the study

Exclusion Criteria

* Patients younger than 18 years of age
* Hyperkalemia defined as a serum potassium exceeding 5.5 mmol/L pre-operatively
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eva Meitner

M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edith Fleischmann, Univ.Prof

Role: STUDY_CHAIR

Medical University of Vienna

Gregor Lindner, MD

Role: STUDY_DIRECTOR

Inselspital Bern, University of Bern

Eva Meitner, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Peter Biesenbach, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Vienna/General Hospital of Vienna

Vienna, Vienna, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MUViennaAnemev

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.